Fidera Ltd. Competitors

In Films for Future (F3) research project, VTT Technical Research Centre of Finland and LUT University are developing new environmentally friendly packaging solutions with 34 industrial partners. The main objective of the project is to develop cellulose-based alternatives to replace the plastic films currently used in packages. The new film material will also meet the demands of the EU’s Packaging and Packaging Waste Directive, which deals with the shift to a circular economy and improving the quality of the environment. The program is funded by the European Regional Development Fund (ERDF).

ATCC is a premier global biological materials and information resource and standards organization and the leading developer and supplier of authenticated cell lines, microorganisms, and associated data for academia, industry, and government. With a history of scientific contributions spanning nearly a century, ATCC offers an unmatched combination of being the world’s largest and most diverse collection of biological reference materials and data, and is a mission-driven, trusted partner that supports and encourages scientific collaboration. ATCC products, services, partnerships, and people provide the global scientific community with credible, advanced, model systems to support complex research and innovations in basic science, drug discovery, translational medicine, and public health. ATCC is a 501(c)3 nonprofit organization with headquarters in Manassas, Virginia, and a research and technology center of excellence in Gaithersburg, Maryland. Visit atcc.org to learn more.

Orion Corporation is a globally operating Finnish pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2023 amounted to EUR 1,190 million and the company had about 3,600 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki. Product related questions and feedback: www.orion.fi/en/contact-us/product-related-questions-and-feedback